PR91501

Keen Eye launches its next-gen platform to accelerate clinical trials with AI-powered Digital Pathology, now fully enabling compliance with good clinical & laboratory practices

PARIS, Sept. 7, 2021 /PRNewswire=KYODO JBN/ --

It enables every actor in Pathology to run digital image analysis in the

context of clinical trials, as in CAP/CLIA laboratories, with unprecedented

efficiency. This AI-platform strengthens Keen Eye's strategic positioning in

the clinical research market subject to GCLP regulations.

Keen Eye, a French health tech company building Deep Learning technology

solutions for research and clinical studies, announces today the launch of

their new platform. This AI (Artificial Intelligence) web-based platform is

dedicated to organizations conducting clinical trial assays in an environment

following GCLP (Good Clinical Laboratory Practices) principles.

By strengthening its portfolio of products and services, Keen Eye takes a true

competitive advantage and reinforces its leadership in AI-based digital image

analysis in Pathology. "It provides a quantum leap in performance while

contributing to regulatory compliance, hence paving the way for better

standards in clinical image analysis. We are proud to have developed the

solution every pharma and CRO has been waiting for," comments Sylvain

Berlemont, CEO and founder of Keen Eye.

Keen Eye's next-generation platform addresses the safety of clinical trial

subjects along with the integrity of data. Quality controls are implemented

throughout workflows and records are signed using electronic signatures. These

features are completed by an audit trail that captures every action performed

on the platform.

For Dr. Jacques Bosq, former head of pathology at Institut Gustave Roussy,

France, "As pathologists, we always put patients' interests first. Keen Eye's

expertise in digital tissue analysis has proven to be a really effective

solution. With this innovative GCLP-compliant platform, pathologists will be

able to perform biomarker detection and quantification in clinical study

protocols in a reliable, standardised and efficient manner."

Keen Eye will showcase the platform capabilities during the "Biomarkers UK"

event organized by Oxford Global, 08 - 09 November 2021.

About Keen Eye

Computational pathology at scale

Founded in 2015, Keen Eye is a health tech company based in Paris, aiming at

bringing AI into every research laboratory, CRO and pharmaceutical company, for

the benefit of biologists, pathologists and patients. Keen Eye is building

decision-support and GCLP-compliant image analysis solutions relying on Deep

Learning technology through web-based platforms. Keen Eye strives to support

the development of new therapies with better, faster and accurate analytics.

For more information: www.keeneye.ai

Follow Keen Eye on

LinkedIn[https://www.linkedin.com/company/keen-eye-technologies/] and

Twitter[https://twitter.com/KeenEyeAI?s=20].

Logo - https://mma.prnewswire.com/media/1609145/Keen_Eye_Logo.jpg

Press Contact: Fanny Sollier, Marketing Manager, press@keeneye.ai

Source: Keen Eye